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The 'restorative' properties of platelets, through the release of 
growth factors, have been implemented in various medical 
areas (dentistry, dermatology, orthopaedic and plastic 
surgery, ophthalmology, etc.), because of their contribution to 
healing various tissues (bone, skin, muscle, tendons, etc.)
[1]
. 
They may be injected, in situ, in the form of platelet 
concentrates, commonly known as PRP (platelet-rich plasma), 




This innovative treatment has piqued clinicians' interest, 
particularly specialists in physical medicine and sports 
traumatology, more so because the production of PRP is 
relatively easy
[2]
. Although intratendinous injection can slightly 
increase the blood concentration of growth factors (particularly 
in vascular endothelial growth factor (VEGF))
[3]
, PRP no 
longer appears on the list of doping products (www.wada-
ama.org), in contrast to other labile blood products. PRP can 
neither improve muscle mass nor alter the transport of oxygen 





This literature review analyses articles on the use of PRP in 
tendinous healing (experimental and clinical studies) 
published between 1 January 2012 and 31 December 2014. 
Several reviews have already appeared relating to earlier 
studies
[5-15]
. The results of both pre-clinical and clinical studies 
were analyzed separately in this review and finally discussed 
together in order to trying to improve this therapeutic modality. 
Articles were searched for using the Medline and Scopus 
databases, by entering, alone and/or combining, the following  
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key words (in  French  and  in  English):  tenocytes,  tendon, 
tendinopathy, PRP, platelet-rich plasma. The papers with high 
level of proofs were preferentially selected. However, due to the 
small number of high level publications, most of the papers were 
accepted and discussed. Forty seven publications relating to the 
use of PRP were selected: 27 pre-clinical in vitro and in vivo 
animal studies and 20 clinical studies in humans. Of these, five 
addressed lateral epicondylitis; two addressed rotator cuff 
tendinopathies; ten dealt with patellar tendinopathies; and three 
looked at calcaneal tendinopathies. 
 
A. Pre-clinical studies 
 
Several lab studies (in vitro and/or on animals) have already 
demonstrated that PRP accelerates the healing process and 
that each growth factor exercises a specific action during the 
tendon healing process
[6]
. However, new studies allow us to 
better understand the effect of PRP on tendon healing. 
 
Mazzocca et al., confirm that different PRPs stimulate cell 
proliferation (muscle, bone and tendon)
[16]
. They did not, 
however, observe any significant difference between the 
different preparations used. In contrast, however, it appears that 
the most concentrated PRPs and those containing white blood 
cells are less efficient than less concentrated PRPs and strongly 
concentrated PRPs without white blood cells. Moreover, this 
same team demonstrated in vitro that the anti-bacterial effect of 
PRP against Staphylococcus aureus, Staphylococcus 
epidermis, Propionibacterium acnes and Methicillin-resistant 
Staphylococcus aureus (MRSA) was not linked to the presence 
of white blood cells
[17]
. 
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In addition to the presence or otherwise of white blood cells in 
PRP, Galliera et al. observed that platelets actively controlled 
the recruitment of leukocytes through the intermediary of 




Dragoo et al., compared the inflammatory reaction caused by 
the infiltration of physiological liquid, blood, PRPs rich in white 
blood cells and PRPs low in white blood cells in rabbit 
tendons
[19]
. Five days after infiltration, the PRPs rich in white 
blood cells lead to a significant inflammatory cellular reaction, 
similar to that observed following blood infiltration. However, 
after 14 days, no difference was observed between the four 
groups. Moreover, McCarrell et al., assessed the effect of four 
PRPs (PRP with intermediate concentration of platelets           
6.10
5
 platelets/µL) and white blood cells; PRP with 
intermediate concentrations of platelets and reduced white 
blood cells; PRP with intermediate concentration of platelets 
and high concentration of white blood cells                              
(12.10
5
 platelets/µL and white blood cells) on the culture of 
horse tendons
[20]
. They noted that the PRP with an 
intermediate concentration of platelets and a high 
concentration of white blood cells led to higher expression of 
pro-inflammatory cytokines and catabolic mediators 
(Interleukin 1β (IL-1β), tumor necrosis factor α (TNF-α)) as 
well as lower collagen synthesis. Moreover, the PRP with high 
concentrations of platelets and white blood cells led to a 
paradoxical effect on collagen synthesis, while also 
presenting an increase in inflammatory mediators. These 
observations were confirmed by Boswell et al., who also 
noted in equine tendon cultures that when platelet 
concentrations were too high (despite low concentrations of 
white blood cells) this reduced tendon metabolism and 
collagen synthesis
[21]
. Finally, Giusti et al., demonstrated in 





 platelets/µL stimulated cell proliferation and 
migration as well as collagen production
[22]
. On the other 
hand, higher platelet concentrations have an inhibitive effect 
both in terms of cell metabolism and collagen synthesis.  
 
In addition to the fact that PRP stimulates cell proliferation 
and collagen synthesis, Jo et al., demonstrated that platelet 





In vitro, however, PRP does not enable the reversal of 
degenerative tendinopathies, characterised by the presence 
of lipid deposits, the accumulation of proteoglycans as well as 
the presence of calcification
[24]
. However, still in vitro, PRP 
does enable the differentiation of tenocyte stem cells and 
inhibits the differentiation in adipocytes, chondrocytes and 




Muto et al., demonstrated that PRP protects against the 
deleterious effects of triamcinolones on cells (reduction in cell 
viability and stimulation of apoptosis) from human rotator 
cuffs
[26]
. Moreover, Carofino et al., studied the effect of two 
different PRPs obtained from human blood, on isolated 
tenocytes in the long head of the biceps
[27]
. These were 
cultured in PRP and either methylprednisolone, lidocaine or 
bupivacaine. They observed that corticoids and, particularly, 
local anaesthetics, alone or combined, reduced the positive 
effects of PRP on tenocyte proliferation and viability. These 
observations were corroborated by those of Bausset et al., 
who showed that local anaesthetics which may be used as 
painkillers during PRP infiltration in clinical practice, could 
compromise the potential therapeutic potential of platelets
[28]
. 
They reduce platelet aggregation but will not interfere with the  
release of their growth factors. Finally, to reduce pain during 
infiltration, they recommend the use of smaller needles 
(30G), because they do not alter platelet function. During the 
study of the effects of PRP on biological activity of fibroblasts 
in human rotator cuffs, Wang et al., observed greater cell 
proliferation and collagen synthesis when PRP was present 
in comparison with foetal veal serum
[29]
. This is supported by 
other studies which show higher cell proliferation, better 
alignment of collagen fibres and better tendon bio-
mechanical properties when PRP is concentrated up to five 
times
[30]
. Kaux et al., demonstrate, using rats' Achilles tendon 
lesion models that the early stages of healing (five days) are 
stimulated by PRP: acute collagen synthesis and better 
traction resistance
[31]
. Within this group of PRP, Fernandez-
Sarmiento et al., observed early healing progress, better 
collagen organisation, and a reduction in fibroblast and 
vascular density
[32]
. These observations are confirmed by 




In an in vitro model on rabbits' tendon cells and in vivo on 
rats' Achilles tendons, Zhang et al., proved that the                   
anti-inflammatory effect of PRP is essentially linked to HGF 
(hepatocyte growth factor)
[34]
. HGF leads to a reduction in the 
expression of cyclooxygenases (COX) 1 and 2, as well as 
prostaglandins (PGE2). 
 
In terms of the growth factors involved in the healing process, 
Solchaga et al., noted that 10µg platelet-derived growth 
factor (PDGF-BB) stimulated healing in rats' Achilles 
tendons, in contrast to 3µg of PDGF-BB, triamcinolone, but 
also PRP
[35]
. In contrast to the deleterious effect of VEGF-
165, Kaux et al., observed that VEGF-111, another VEGF-A 
isoform, stimulated the early phases of the healing process in 





Finally, in addition to platelet effectiveness on healing in line 
with a chemical tendinopathy model (platelet and calcaneal 
tendons in rats), Dallaudière et al., did not show evidence of 




In conclusion, the majority of pre-clinical studies show a 
beneficial effect of PRP on the proliferation of tenocytes, 
collagen synthesis and the tendon healing process. In order 
to optimise efficiency, it would appear that platelet 
concentration should be lower than 10
6
 platelets/µL and that 
white blood cells should be absent. 
 
B. Clinical studies: 
 
PRPs are used in the context of chronic tendinopathies in 
injectable form
[38]
. For some years, it has been used 
increasingly regularly, more specifically in the area of 
physical medicine and sports traumatology
[11]
. The objective 
is to heal tendinopathies which are particularly resistant to 
other conservative treatments (eccentric physical therapy, 
shock waves, etc.) and thus to avoid surgery. In a certain 
number of cases, the aim is also to reduce the duration of 
functional impotence and to encourage an early return to 
physical activity. However, currently the use of these PRPs 








In a prospective three-month study, without a control group  
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Tendinopathies and PRP 
 
P9 
(level 3), Silvestre et al., report on the clinical evolution of 26 
patients who had suffered from evolving lateral epicondylitis 
for more than six months and who had received PRP 
infiltration
[39]
. They noted that pain, assessed on simple verbal 
scale, was significantly improved, a well as the Quick 
disabilities of the arm, shoulder and hand (DASH) score. 
Ultrasound observations showed the fissure had disappeared 
in 65% of patients, as well as a reduction in the pathological 
area and Doppler hyperaemia in 27% of subjects. In their 
controlled, randomised study (level 1), Omar et al., compared 
the effect of PRP or corticoid infiltration in 30 patients over a 
period of six weeks. They observed a positive change on the 
visual analogue scale (VAS) and DASH score within the two 




In their longitudinal six-month study (level 4) of six patients 
who had received an injection of 3ml of PRP under ultrasound, 
Chaudhury et al., observed a positive change in the tendon's 
ultrasound structure, with a trend towards increased 




The randomised, controlled, double-blind study (level 1) by 
Krogh et al., did not show any difference after PRP, corticoid 
or physiological liquid infiltration in the context of epicondylitis 
over a period of three months
[42]
. However, patients who 
received PRP infiltration started to improve, while those who 
received corticoid infiltration (resulting in fast improvement in 
pain in the very short term), indicated the progressive return of 
pain.  
 
Recently, in their randomised and controlled study (level 1) of 
230 patients, Mishra et al., compared a PRP group to an 
active control group receiving an injection of local 
anaesthetic
[43]
. After 12 weeks, there was no difference 
between the two groups in terms of VAS when extending the 
wrist against resistance and the patient-rated tennis elbow 
evaluation (PRTEE) self-assessment score. At the end of the 
24 week follow-up period, significantly positive clinical 
changes were observed in the PRP group of patients. 
 
To summarise, although studies with low levels of proof on the 
use of PRP for lateral epicondylitis currently appear to be 
favourable, the small number of series with a high standard of 
proof are still contradictory and more randomised controlled 
studies are still needed. 
 
Tendon lesions in rotator cuffs 
 
The randomised, controlled study by Rha et al., (level 1) 
compared the value of two PRP infiltrations in 39 patients 
affected by tendinopathy of the rotator cuff, compared to two 
dry needle insertions guided by ultrasound, over a period of 
six months
[44]
. After the first intervention, the two groups 
evolved identically. However, after the second infiltration of 
PRP, a clinical improvement (in pain and mobility of the 
shoulder) was observed in comparison with the control group. 
 
In their randomised, controlled study (level 1), Kesikburun              
et al., assessed the effect in 40 patients of an injection of 
either PRP or physiological liquid
[45]
. After 12 months, no 
difference could be observed between the two groups in terms 
of pain, quality of life, handicap and range of motion of the 
shoulder. 
 
To summarise, the very small number of studies with a high 
standard of proof on the use of PRP for tendinopathies of the 
rotator cuff currently remain contradictory. Up to now, it 




The prospective, randomised and controlled (level 1) study by 
Almeida et al., specified that PRP improved healing at the 
puncture site (patellar tendon) required for ligamentoplasties 




The prospective 18-month study (level 3) by Gosens et al., 
compared 14 patients who had already received treatment 
(cortocoids or ethoxysclerol and/or surgery) with 22 patients 
who had never had any infiltrative or surgical treatment
[47]
. 
They all took part in eccentric physical therapy before and 
after the injection. After four weeks, the patients were able to 
gradually restart their sporting or recreational activities. An 
improvement in Victorian Institute of Sport Assessment for 
patellar tendinopathy (VISA-P) scores, VAS and pain during 
daily activities was seen in both groups, but more significantly 
so for the patients who had never had 'invasive' treatment 
before PRP infiltration. 
 
Rowan et al., report on the positive development and return to 
prior athletic form within six months of a 23-year old elite 
athlete (level 4) who had received multidisciplinary treatment 




In their longitudinal study (level 3) of 46 patients who had 
received three PRP infiltrations two weeks apart, with a 
minimum monitoring period of up to 36 months (average of 49 
± 8 months), Filardo et al., demonstrated a positive evolution 
two months after infiltration, continuing at six months and until 
the end of the follow up period
[49]
. Eighty percent of patients 
had resumed their sporting activities. Patients with bilateral 
problems and whose symptoms had lasted the longest, 
however, evolved less well. 
 
In their randomised and controlled study (level 1), Vetrano et 
al., assessed the effect of PRP over three treatments with 
focal shock waves in 46 patients suffering from patellar 
tendinopathy
[50]
. After two months, the two groups evolved in a 
similar way. However, after six and twelve months of follow 
up, the PRP patients presented better progress than the group 
treated with shock waves. 
 
As part of their randomised and controlled study (level 1), 
Dragoo et al., compared the effect of PRP infiltration to the 
introduction of a dry needle guided by ultrasound in 23 
patients
[51]
. The two groups took part in eccentric physical 
rehabilitation following infiltration. Although evolution at 12 
weeks is better in the PRP group, this beneficial effect 
dissipates over time and, at 26 weeks, no difference could be 
seen between the two groups. 
 
Charousset et al., followed 28 high level athletes (level 4) who 
received three consecutive infiltrations of PRP under 
ultrasound control
[52]
. At the end of the two year follow-up 
period, the subjects reported improvements in their symptoms 
and function, enabling them to get back to their earlier athletic 
condition more quickly. Moreover, they observed that tendons 
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Tendinopathies and PRP 
Kaux et al., followed 20 patients suffering from chronic 
patellar tendinopathy in a longitudinal cohort study (level 3) 
following 'standardised' PRP infiltration, obtained by an 
apheresis machine combined with progressively intense sub-
maximal eccentric physical exercise
[53]
. Evolution at six 
weeks and three months showed a significant reduction in 
pain and self-assessed scores, as well as in pain during 
maximal eccentric effort applied to the quadriceps, but no 
imaging improvements. The youngest patients appeared to 
improve more following this PRP treatment. 
 
Two longitudinal studies (level 3 and 4) relating to post-
infiltration physical therapy have been published
[54,55]
. The 
two programmes were based on eccentric physical therapy 
following a period of pain-relieving physical therapy and 
recovery of normal range of movement in the joint. However, 
the protocol used by Kaux et al., begins eccentric sub-
maximal physical therapy earlier than that of Van Ark et al. 
These eccentric exercises are gradually combined with 
isometric work followed by concentric strengthening work on 
the quadriceps as well as proprioceptive exercises. At the 
end of the physical therapy treatment, which is supervised by 
a physiotherapist, the patients can continue self-led 
treatment in the long term. 
 
Bowman et al., report that three patients (level 4) who had 
already received PRP infiltration for unresponsive patellar 
tendinopathy, experienced an increase in painful symptoms 
leading to an inability to take part in sport, but also in 
increase in the thickness of the tendon and, in one patient, 
osteolysis of the patellar pole
[56]
.  Fink et al., also observed 
an osteolysis of the distal pole of the patella in one patient 
who had worsening pain and thickening of the patellar tendon 
after one infiltration of PRP (Level 4). Kaux et al., also 
published (level 4) the case of a particularly exuberant 
inflammatory reaction in a Type-1 diabetic patient following a 
PRP infiltration for patellar tendinopathy. Evolution was 





To summarise, studies on the use of PRP for patellar 
tendinopathies currently appear to be favourable, but high 
standard of proof studies remain fairly contradictory. It 
appears that eccentric physical therapy is necessary 





Over a period of three months, Silvestre et al., followed 32 
patients (level 3) with Achilles tendonitis who had received 
ultrasound-guided PRP infiltration
[58]
. After one month, 22 
patients were completely cured, and after two months, 28 
were completely cured, with a favourable evolution in 
tendinous echostructure and a reduction in Doppler 
hyperaemia at three months. Only four patients did not see 
any clinical improvement and were operated upon. 
 
In their four-year longitudinal study (level 3) of 27 patients 
suffering from chronic Achilles tendinopathy, following three 
PRP infiltrations two weeks apart, Filardo et al., reported very 
positive changes in self-assessed status
[59]
. The patients who 
had suffered for the longest had more difficulties in returning 








Finally, Murawski et al.,  conducted  a  retrospective  study 
(level 4) on 32 patients over six months
[60]
. At the end of the 
follow-up period, 25 subjects were asymptomatic and had 
resumed their sporting activities. The seven others 
experienced no improvements in their pain and were 
operated upon. Only four patients presented MRI imaging 
improvements. 
 
To summarise, studies on the use of PRP for calcaneal 
tendinopathies currently appear to be positive. However, no 
high standard of proof studies have taken place since the 
unfavourable study by de Vos in 2010 which did not report 
any improvement after an infiltration of leukocyte rich PRP 






By releasing different platelet growth factors, PRPs are a 
new treatment for chronic tendinopathies
[15]
: the ease of use, 
the relatively low cost, and the low invasive nature of the 
treatment are complementary arguments. Up to now, the 
reported side effects remain benign
[56,57]
. No relationship has 
been established between growth factor and possible 
carcinogenesis. Care should be taken, however, to ensure 
that any undesirable side effects are actually published. 
Currently, only a bleeding disorder, a disorder of the skin 
covering (infection, psoriasis) next to the lesion could be 
reasonably considered as contra-indication of the use of PRP 
in the treatment of tendinopathies. This treatment has been 
used for several years in different surgical specialities with 
favourable clinical results
[62,63]
. Despite the effectiveness of 
PRP on tissue regeneration in vitro and in animals, little 
clinical proof is currently available in relation to 
tendinopathies.  
 
The rare controlled, randomised and blind studies which exist 
appear to contradict one another
[40,42,44,50,51,61].
 Can the type 
of tendon change the healing response? Would this be 
different for certain voluminous tendons (patellar) compared 
to others (epicondylian, rotator cuff, etc.)
[73]
? Studies on the 
patellar tendon appear to be more positive than other 
tendons. However, as already observed in previous reviews 
on PRP
[5-15]
, the more recent studies cannot conclude that 
PRP is really efficient in the treatment of tendinopathy, even 
if most of the low level studies remain very encouraging. 
Moreover, many of the authors of the articles reporting 
success of PRP application (essentially with leukocytes rich 
PRP) have conflicts of interest. PRPs are injected into the 
tendinous lesion, possibly guided by ultrasound (under 
aseptic conditions) to improve the accuracy of this treatment 
by a correct positioning of the needle
[74-76]
. A percutaneous 
tenotomy using a needle (guided by ultrasound) could also 




Moreover, studies appear to be difficult to compare because 
there is no consensus on preparatory methods, qualitative 
characteristics of PRP (volume, platelet concentration, 
presence of leukocytes and erythrocytes
[64-67]
, the infiltration 
technique, or the post-injection therapy protocol
[11,15,54,55,68]
). 
Indeed, different techniques collate different platelet volumes 
and concentrations: lab techniques which have been used in 
the past from an analytical perspective can be distinguished 
from recent commercial techniques
[64-67]
. Currently, the 
optimal concentration of platelets used in the treatment of 
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  However, the literature raises the following elements: 
 a platelet concentration less than 10
6
 platelets/µL (three 
to four times the blood platelet concentration) would be 
optimal, while a concentration higher than 12.10
5
 




 a total lack of white blood cells, which are likely to slow 
down healing due to the early occurrence of a higher 
local inflammatory reaction
[19,70]
 and the presence of 
pro-inflammatory factors (cytokines and 
metalloproteinases) likely to damage the extracellular 
matrix
[65,71]




 the lack of red blood cells because these, once lysed, 
release various free radicals, similar to those of 





Anti-inflammatories are forbidden from Day -10  to Day +21, 
due to their inhibitory effect on PRP action
[1,78]
. It appears 
that studies where eccentric physical therapy takes place 
report better results than those with rest or classic 
rehabilitation techniques
[54,55]
; in fact, the PRPs trigger a 





The IOC coordinated the drafting of three articles on 
PRP
[75,79,80]
 confirming the medical-sporting value of this 
treatment. It recommends that the injection is guided by 
ultrasound in order to ensure the correct position of the 
needle
[75]
. A few minutes after infiltration, PRPs diffuse 
beyond the infiltrated area and the lesion site, singularly 
questioning the value of ultrasound-guided infiltrations
[81]
. 
Moreover, currently there is no consensus on the 




Experimentally, PRP, through the release of different growth 
factors, stimulates tendinous healing. This treatment should 
optimise healing in pathological human tendons. It should be 
examined whether PRP improve tendinous healing in the 
same way in humans as in animals
[82]
. Up to now, even if 
PRP seems to be safe and efficient to treat chronic 
tendinopathies non-responsive to classical conservative 
treatments, further high standard of proof series should 
enable this promising technique to be standardised and to 
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COX:   Cyclooxygenase 
DASH:  The Disabilities of the Arm, Shoulder and Hand Score 
HGF:   Hepatocyte Growth Factor 
IL-1β:  Interleukin 1β 
MRSA:   Methicillin-Resistant Staphylococcus aureas  
MRI:   Magnetic Resonance Imaging 
PDGF-BB:  Platelet-Derived Growth Factor BB 
PGE2:   Prostaglandin E2 
PRP:   Platelet Rich Plasma 
PRTEE:   Patient-rated Tennis Elbow Evaluation 
TGF-β:   Transforming Growth Factor β 
TNF-α:   Tumor Necrosis Factor α 
VAS:   Visual Analogic Scale 
VEGF:   Vascular Endothelial Growth Factor 
VISA-P:   Victorian Institute of Sport Assessment for patellar tendinopathy 
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